HomeCompareBMY vs PAA

BMY vs PAA: Dividend Comparison 2026

BMY yields 4.17% · PAA yields 6.93%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAA wins by $6.59M in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
PAA
PAA
● Live price
6.93%
Share price
$22.47
Annual div
$1.56
5Y div CAGR
57%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.71M
Annual income
$5,114,230.35
Full PAA calculator →

Portfolio growth — BMY vs PAA

📍 PAA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYPAA
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + PAA cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
PAA pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
PAA
Annual income on $10K today (after 15% tax)
$589.17/yr
After 10yr DRIP, annual income (after tax)
$4,347,095.80/yr
At 15% tax rate, PAA beats the other by $4,313,245.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + PAA for your $10,000?

BMY: 50%PAA: 50%
100% PAA50/50100% BMY
Portfolio after 10yr
$3.41M
Annual income
$2,577,027.01/yr
Blended yield
75.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PAA right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
PAA
Analyst Ratings
1
Strong
23
Buy
16
Hold
2
Sell
Consensus: Buy
Price Target
$21.83
-2.8% upside vs current
Range: $17.00 — $25.00
Altman Z
2.3
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
PAA buys
0
No recent congressional trades found for BMY or PAA in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYPAA
Forward yield4.17%6.93%
Annual dividend / share$2.49$1.56
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%57%
Portfolio after 10y$120.5K$6.71M
Annual income after 10y$39,823.66$5,114,230.35
Total dividends collected$91.0K$6.54M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$21.83

Year-by-year: BMY vs PAA ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrPAA PortfolioPAA Income/yrGap
1← crossover$11,271$571.12$11,788$1,088.24$517.00PAA
2$12,884$824.20$14,496$1,882.30$1.6KPAA
3$14,993$1,206.32$18,907$3,396.22$3.9KPAA
4$17,839$1,797.27$26,730$6,499.60$8.9KPAA
5$21,826$2,738.11$42,084$13,482.87$20.3KPAA
6$27,643$4,289.31$76,177$31,147.09$48.5KPAA
7$36,534$6,955.64$164,235$82,725.90$127.7KPAA
8$50,861$11,770.13$437,430$261,698.43$386.6KPAA
9$75,402$20,980.23$1,490,777$1,022,727.50$1.42MPAA
10$120,504$39,823.66$6,709,362$5,114,230.35$6.59MPAA

BMY vs PAA: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

PAAStock

Plains All American Pipeline, L.P., through its subsidiaries, engages in the pipeline transportation, terminalling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates in two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and at times on barges or railcars. This segment provides terminalling, storage, and other facilities-related services, as well as merchant activities. As of December 31, 2021, this segment owned and leased 18,300 miles of active crude oil transportation pipelines and gathering systems, as well as an additional 110 miles of pipelines that supports crude oil storage and terminalling facilities; 74 million barrels of commercial crude oil storage capacity; 38 million barrels of active, above-ground tank capacity; four marine facilities; a condensate processing facility; seven crude oil rail terminals and 2,100 crude oil railcars; and 640 trucks and 1,275 trailers. The Natural Gas Liquids segment engages in the natural gas processing, NGL fractionation, storage, transportation, and terminalling activities. As of December 31, 2021, this segment owned and operated four natural gas processing plants; nine fractionation plants; 28 million barrels of NGL storage capacity; approximately 1,620 miles of active NGL transportation pipelines, as well as an additional 55 miles of pipeline that supports NGL storage facilities; 16 NGL rail terminals and approximately 3,900 NGL rail cars; and approximately 220 trailers. The company was founded in 1981 and is headquartered in Houston, Texas. Plains All American Pipeline, L.P. operates as a subsidiary of Plains GP Holdings, L.P.

Full PAA Calculator →
📬

Get this BMY vs PAA comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.